Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.

ABSTRACT:

Importance

In the Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved), empagliflozin significantly reduced hospitalizations for heart failure while improving patient-reported health status compared with placebo. The long-term cost-effectiveness of empagliflozin among patients who have heart failure with preserved ejection fraction (HFpEF) remains unclear.

Objective

To estimate the cost-effectiveness of empagliflozin in patients with HFpEF.

Design, setting, and participants

This cost-effectiveness analysis performed from October 2021 to April 2022 included a Markov model using estimates of treatment efficacy, event probabilities, and utilities from EMPEROR-Preserved and published literature. Costs were

SUBMITTER: Zheng J 

PROVIDER: S-EPMC9641590 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature